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Abstract 
Introduction: Programmes that merge management of Human Immunodeficiency Virus (HIV) and tuberculosis (TB) 
aim to improve HIV/TB co-infected patients’ access to comprehensive treatment. However, several reports from sub-
Saharan Africa (SSA) indicate suboptimal uptake of antiretroviral therapy (ART) even after integration of HIV and TB 
treatment. This study assessed ART uptake, its barriers and enablers in programmes integrating TB and HIV treatment 
in SSA.
Method: A systematic review was performed. Seven databases were searched for eligible quantitative, qualitative 
and mixed-methods studies published from March 2004 through July 2019. Random-effects meta-analysis was used 
to obtain pooled estimates of ART uptake. A thematic approach was used to analyse and synthesise data on barriers 
and enablers.
Results: Of 5139 references identified, 27 were included in the review: 23/27 estimated ART uptake and 10/27 
assessed barriers to and/or enablers of ART uptake. The pooled ART uptake was 53% (95% CI: 42, 63%) and between-
study heterogeneity was high  (I2 = 99.71%, p < 0.001). WHO guideline on collaborative TB/HIV activities and sample 
size were associated with heterogeneity. There were statistically significant subgroup effects with high heterogene-
ity after subgroup analyses by region, guideline on collaborative TB/HIV activities, study design, and sample size. The 
most frequently described socioeconomic and individual level barriers to ART uptake were stigma, low income, and 
younger age group. The most frequently reported health system-related barriers were limited staff capacity, short-
ages in medical supplies, lack of infrastructure, and poor adherence to or lack of treatment guidelines. Clinical barriers 
included intolerance to anti-TB drugs, fear of drug toxicity, and contraindications to antiretrovirals. Health system ena-
blers included good management of the procurement, supply, and dispensation chain; convenience and accessibility 
of treatment services; and strong staff capacity. Availability of psychosocial support was the most frequently reported 
enabler of uptake at the community level.
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Introduction
Among persons living with HIV/AIDS (PLWHA) in low-
income settings, tuberculosis (TB) remains the principal 
cause of mortality [1–3]. In 2017, PLWHA accounted for 
900, 000 (9%) of the estimated 10 million new TB dis-
ease cases worldwide [4] and of the 900,000 co-infected 
patients, up to 300,000 (33.3%) died because of TB [5]. 
The majority of these co-infected patients reside in sub-
Saharan Africa (SSA) and according to the World Health 
Organization (WHO) global TB report of 2018, up to 
72% of all patients co-infected with HIV and TB resided 
in the region [4].
From a therapeutic perspective, low-income settings 
of SSA initially relied on separate vertical HIV and TB 
programmes to deliver concurrent HIV and TB treat-
ment to co-infected patients [6–11]. In 2004, based on 
evidence suggesting that better treatment outcomes are 
observed when both programmes are integrated, the 
World Health Organisation (WHO) published policy 
guidelines to steer the integration of HIV and TB treat-
ment services [12]. Various approaches of delivering inte-
grated services have been proposed and vary from having 
the services within one health facility to a one-stop-shop 
strategy in which the services are provided as a sin-
gle package by the same healthcare team [13]. The 2004 
WHO guidelines comprised activities aimed at integrat-
ing TB services into HIV care settings with the objective 
of decreasing the burden of TB in PLWHA and integrat-
ing HIV services into TB control programmes with the 
objective of decreasing the burden of HIV in TB patients 
[12]. To reduce the burden of TB in PLWHA, WHO rec-
ommended intensified TB case-finding, isoniazid preven-
tive therapy and infection control in healthcare settings. 
To reduce the burden of HIV in TB patients, WHO made 
an emphasis on HIV counselling and testing and HIV 
prevention methods for all TB patients, and cotrimoxa-
zole preventive therapy and HIV/AIDS care and support 
(including ART) for co-infected patients [12]. It is worth 
noting that these initial guidelines were based on incom-
plete evidence and were therefore meant to serve as pro-
visional guidelines [14].
In 2012, WHO issued a review of the 2004 guide-
lines [14]. Overall, the updated policy employs the same 
framework as the interim policy but emphasized on 
strategies for delivering integrated HIV/TB treatment, 
preferably at the same time and location. The new guide-
lines encourage the establishment of mechanisms of 
delivering both HIV and TB treatment within other pro-
grammes such as maternal and child health, and prison 
health services [14]. Furthermore, monitoring and evalu-
ation of activities linked with integrated HIV/TB treat-
ment are expected to be based on standardized indicators 
and reporting formats. In this light, it is worth noting that 
uptake of and adherence to treatment are important indi-
cators of the quality and therapeutic outcomes of inte-
grated care [14]. WHO recommends that HIV-infected 
TB patients should be initiated on ART irrespective of 
their CD4 count, as timely initiation of ART during TB 
therapy has been shown to significantly improve survival 
[15]. ART should be started within 8  weeks of initia-
tion of anti-TB treatment and in TB patients with a CD4 
count of less than 50cells/mm3, ART should be started 
within 2 weeks after the onset of anti-TB treatment [15–
17]. ART is associated with severe adverse events in HIV 
patients with TB meningitis so ART in these cases should 
be delayed. In the event of TB-associated immune recon-
stitution inflammatory syndrome (IRIS), anti-TB and 
ART should be continued as IRIS is typically self-limiting 
[18–20].
Reports on integrated TB/HIV treatment services in 
SSA have tended to focus on quantitative data on cover-
age and functionality, with scarce exploration of factors 
affecting ART uptake which is an important indicator of 
the success of integrated TB/HIV treatment. The need to 
investigate this indicator in SSA is further supported by 
compelling reports from the region which suggest subop-
timal uptake of antiretroviral therapy (ART) even when 
HIV and TB treatment services are integrated [21, 22]. 
This study sought to estimate ART uptake in programmes 
integrating treatment of HIV and TB in SSA and to sum-
marize existing evidence on the barriers to and facilitat-
ing factors for the uptake of ART in these programmes.
Methods
Search strategy
Medline, Embase, Cochrane, Popline, Scopus, Global 
Health and Africa journal online databases were searched 
extensively to include peer-reviewed studies published 
Conclusions: In SSA, programmes integrating treatment of TB and HIV do not, in general, achieve high ART uptake 
but we observe a net improvement in uptake after WHO issued the 2012 guidelines on collaborative TB/HIV activities. 
The recurrence of specific modifiable system-level and patient-level factors in the literature reveals key intervention 
points to improve ART uptake in these programmes.
Systematic review registration: CRD42019131933.
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from March 2004 (when WHO first issued recommen-
dations governing integrated HIV/TB care) through July 
2019. The search terms and their variations that were 
used in combination are shown on Additional file 1. Arti-
cles retrieved from the search were exported to and saved 
on Mendeley desktop software version 1.19.8.0.
Selection of studies
Two investigators (BMK and CAD) independently 
screened the titles and/or abstracts and when neces-
sary, the full texts of studies identified using the search 
strategy, to assess each study’s eligibility for inclusion. 
The assessments were made using selection criteria that 
were developed from clearly defined study population 
(participants), intervention and outcomes of interest, 
study design, research methods, setting and language. 
The inclusion criteria were as follows: randomized trials 
and observational (cross-sectional and cohort) studies 
published in English language; studies using quantitative, 
qualitative, or mixed research methods; studies describ-
ing integrated treatment of HIV and TB (the delivery 
of both HIV and TB treatment at the same time, by the 
same health team, at the same location) in sub-Saharan 
Africa; studies involving adults newly diagnosed with 
HIV/ pulmonary TB co-infection or pulmonary TB 
patients on anti-TB drugs who are newly diagnosed with 
HIV and require ART; studies involving healthcare pro-
viders and other stakeholders involved in the delivery of 
integrated HIV/TB treatment; studies with at least one 
of the outcomes of interest (ART uptake, barriers to ART 
uptake, or enablers of ART uptake). Exclusion criteria 
were as follows: studies involving TB patients only or 
HIV infected persons only; studies involving other forms 
of TB other than pulmonary TB; studies involving deliv-
ery of only ART or only anti-TB drugs; and studies in 
which HIV and TB treatment are delivered via separate 
vertical programmes. Conference abstracts, editorials, 
policy briefs, policy discussions, bulletins, grey literature, 
and letters to editors were excluded. The reference lists 
of eligible articles were hand searched to identify other 
eligible studies.
Assessment of methodological quality
BMK and CAD independently assessed the methodo-
logical quality of the studies. The quality of qualitative 
studies was graded using the Critical Appraisal Skills Pro-
gramme [23] while those of interventional and observa-
tional studies were assessed using their respective quality 
assessment tools as per the National Health Institute 
(National Heart, Lung, and Blood Institute) [24]. For 
mixed-methods studies, the qualities of the qualitative 
and quantitative components were separately assessed 
using appropriate tools as described above.
Data extraction
Data extraction forms and definitions of key terms were 
developed to standardise the data collection process. 
Two extraction forms were developed on Microsoft 
Excel 2016: one for qualitative data (barriers and ena-
blers) and one for quantitative data (uptake of ART). 
Each of the forms was piloted using three studies. BMK 
and CAD independently extracted relevant data from 
each retained article and saved the data on the Microsoft 
Excel forms. Data entered in the forms was then harmo-
nised and subsequently double-checked for accuracy by a 
third investigator (NFT). Quantitative data was exported 
to STATA 15. Data on publication details and outcomes 
of interest were extracted. Data on publication details 
included first author name, publication year, journal ref-
erence, country and place of study, year of study, study 
design, study area and setting, study population, sample 
size, characteristics of patients (such as age and sex dis-
tribution etc.), ART initiation policy and WHO TB/HIV 
management policy, as well as limitations and strengths 
of studies. ‘ART initiation policy’ was considered a binary 
variable with the categories being initiation prior to the 
test and treat policy of 2015 (ART initiation depended 
on CD4 count) versus initiation following the test and 
treat policy guidelines of 2015. ‘WHO TB/HIV manage-
ment policy’ was also considered a binary variable with 
the categories being treatment following 2004 guidelines 
versus treatment following 2012 guidelines. Data on out-
comes of interest included ART uptake (measured as the 
reported proportion of persons diagnosed HIV seroposi-
tive and found eligible for HIV treatment and who effec-
tively initiated ART; from 2015 when universal ART was 
recommended, all persons diagnosed HIV seropositive 
were eligible to initiate ART), barriers to ART uptake and 
enablers of ART uptake. For studies providing estimates 
on ART initiation, when a study provided data spanning 
different policy periods or timings of ART initiation, we 
recorded and analysed the data for each period or tim-
ing separately. For qualitative studies, specific barriers 
and enablers were extracted as reported in the studies. As 
concerns quantitative studies investigating factors asso-
ciated with uptake of ART, factors associated with poor 
uptake were considered as barriers while factors associ-
ated with good uptake were considered as enablers.
Data analysis and synthesis
A thematic approach was used to analyse and synthesise 
data on barriers to and enablers of uptake of ART. This 
approach was also employed for studies that quantita-
tively assessed factors associated with ART uptake. BMK 
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and CAD developed the initial coding framework on 
Microsoft Excel 2016 by reading through the results of all 
the eligible studies to identify the main themes. Based on 
the initial coding, broad themes were developed under 
which all text units were iteratively grouped into one of 
the broad themes. Each theme and the text units were 
then further analyzed and amended to develop more 
themes and sub-themes.
Meta-analysis was used to obtain the pooled estimate 
for ART uptake. ART uptake was represented on a forest 
plot and the risk of publication bias was assessed using 
a funnel plot. The degree of between-study variabil-
ity in the ART uptake was assessed by visual inspection 
of the forest plots and interpretation of the I2 statistic 
from meta-analysis (none  (I2 < 25%), low (25 ≤  I2 ≤ 49%), 
moderate (50 ≤  I2 ≤ 74%) or high  (I2 ≥ 75%). The p-value 
for heterogeneity was used to determine whether the 
between-study variability is associated with variations 
in the size of ART uptake across studies. Pooled esti-
mates of ART uptake categorized by variables such as 
study design, study population size, region, study setting, 
and WHO guideline on collaborative TB/HIV activities 
were also assessed. Meta-regression was used to inves-
tigate possible associations between these variables and 
between-study heterogeneity in ART uptake.
This study has been reported as per the Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
sis (PRISMA) guidelines (Additional file 2). The protocol 
for this review was registered with the Prospective Regis-
try of Systematic Reviews (PROSPERO) and the registra-
tion number is CRD42019131933.
Results
Overview of search output
The search yielded a total of 5139 articles. Figure 1 is a 
PRISMA flowchart detailing the process by which we 
arrived at the final list of 27 studies. After removing 
duplicates, screening the titles and abstracts of the arti-
cles, excluding ineligible articles, and manually searching 
the reference lists of eligible articles, a harmonised list 
of 27 studies with one of more outcomes of interest was 
retained for analysis: 4 assessed barriers and/or enablers 
of ART uptake, 17 estimated ART uptake and 6 assessed 
both ART uptake and barriers and/or enablers. Overall, 
twenty-three (23/27) studies estimated ART uptake and 
involved 22847 TB/HIV co-infected patients, but the 
analysis was conducted on 21630/22847 (94.7%) partici-
pants who had full relevant data. Thirteen (14/23) of the 
studies were from East Africa, 4/23 from Southern Africa 
and 3/23 from Central Africa and 2/23 from West Africa. 
Table 1 summarizes these studies.
Overall, ten (10/27) studies provided data on barriers to 
and/or enablers of uptake of ART. The data was obtained 
from a total of 3514 participants and 12 focus group dis-
cussions. Six (6/10) of the studies were conducted in East 
Africa, 2/10 in South Africa, 1/10 in West Africa and 
1/10 in Central Africa. Table 2 summarizes the studies. 
Methodological quality of studies
Nineteen of the 23 (19/23) studies with estimates of ART 
uptake were of moderate quality (Table  3). Table  3 also 
includes the quality assessment of three studies [22, 31, 
34] that used quantitative methods to assess factors asso-
ciated with (barriers to and/or enablers of ) ART uptake. 
The other seven of the ten (7/10) studies that assessed 
barriers to and/or enablers of ART uptake used qualita-
tive methods to assess the study outcomes and three-
quarters of these studies were of moderate quality 
(Table 4).
ART uptake
A total of 28 estimates were obtained from the 23 stud-
ies that estimated ART uptake. The individual study esti-
mates of uptake and the reasons for having 28 estimates 
from 23 studies are detailed on Table 1. Some reasons for 
the discrepancy included: same study evaluating uptake 
at two different periods of implementing the integration 
policy [25], study reporting of uptake at different facili-
ties [26], and study evaluating ART initiation in cohorts 
with different timings of ART initiation [27]. Uptake of 
ART ranged from 18.0 to 98.9%, with a pooled estimate 
of 53% (95% CI: 42, 63%;  I2 = 99.71%, p < 0.001) and high 
between-study heterogeneity  (Fig.  2). The proportion of 
between-study heterogeneity explained by sample size 
(< 1000 versus 1000 or more) was 28.26%; p-value = 0.002 
(p < 0.05), indicating strong evidence of an association 
between sample size and between-study variability in 
ART uptake. The proportion of between-study hetero-
geneity explained by WHO guideline on collaborative 
TB/HIV activities (interim versus revised guidelines) 
was 14.09%; p-value = 0.031 (p < 0.05), indicating much 
weaker evidence of an association between the covariate 
‘WHO guideline on collaborative TB/HIV activities’ and 
between-study variability in ART uptake. The proportion 
of between-study heterogeneity explained by setting of 
study  (categorized as rural, urban, rural and urban) was 
− 4.82%; p-value = 0.840 (> 0.05), indicating no evidence 
of an association between study setting and between-
study variability in ART uptake. 
The results of subgroup analyses are shown on Addi-
tional  files  3, 4, 5, 6, 7. There was no statistically sig-
nificant difference in pooled ART uptake stratified by 
study setting i.e., urban versus rural versus urban and 
rural (Additional file  3). As shown in Additional file  4, 
subgroup analysis by region revealed statistically signifi-
cant subgroup effects (p = 0.021). Pooled ART uptake 
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in Southern Africa and Central Africa were comparable 
(68%, 95% CI: 47, 86 and 65%, 95% CI: 42, 84% respec-
tively) and much higher than the pooled estimates from 
East Africa (49%, 95% CI: 41, 57%) and West Africa 
(43%, 95% CI: 40, 46%). Pooled ART uptake for studies 
under the revised WHO guidelines on collaborative TB/
HIV activities (67%, 95% CI: 52, 80%) was much higher 
than that for studies based on the 2004 interim guide-
lines (47%, 95% CI: 40, 53%) as shown in Additional 
file  5. The subgroup effect was statistically significant 
(p = 0.013). Additional file 6 shows very strong evidence 
of a statistically significant subgroup effect with subgroup 
analysis by study design (p < 0.0001). The highest pooled 
uptake was in retrospective studies (60%, 95% CI: 52, 
68%). The pooled estimate for prospective cohort studies 
was similar to the overall pooled ART uptake (53%, 95% 
CI: 34, 72%). As shown in additional file  7,  the pooled 
ART uptake for studies with sample size < 1000 (63%, 95% 
CI: 52, 74%) was much higher than that of studies with 
sample  ≥1000 (39%, 95% CI: 32, 46%). There was very 
strong evidence of a statistically significant subgroup 
Records identified through database searching: 5139
Scopus-1336; Medline (Ovid)-508; Popline-304; Global Health-1242; Embase-687; 
Cochrane-12; African Journal Online-1050 
4990 records 
Title and abstract screened
515 records  
Full text reviewed
27 records retained. 
4: barriers and/or enablers. 
6: ART uptake and barriers and/or 
enablers 























7 added from references of relevant studies
 4475 excluded after screening titles and abstracts 
Excluded: 488
Ineligible study designs: editorials, conference 
abstracts, commentaries, etc: 433 
Data provided not adequate/relevant: 55
156 duplicates excluded
Fig. 1 PRISMA flowchart showing process of selection of studies that were reviewed in the systematic review of barriers to and enablers of uptake 
of antiretroviral therapy in the context of integrated HIV and tuberculosis treatment among adults in sub-Saharan Africa
Page 6 of 17Kadia et al. AIDS Research and Therapy           (2021) 18:85 
Table 1 Studies with estimates of ART uptake in the context of integrated HIV/TB treatment among adults in SSA
ART antiretroviral therapy, PMTCT prevention of maternal-to-child transmission, SSA sub-Saharan Africa






1 Burnett, 2018 Rural Uganda Cross-sectional 179 103 47.7
2 Ferroussier, 2013 Rural and urban Benin Retrospective cohort 1255 1111 42
3 Gasana, 2008 Rural Rwanda Prospective cohort 125 125 43.2
4 Harris, 2008 Urban Zambia Prospective cohort 1006 1006 59
5 Shaffer, 2011 Rural Kenya Secondary analyses of retrospec-
tive cohort data
1911 1911 35.8
6 Simieneh, 2017 Urban Ethiopia Cross-sectional 246 246 31.7
7 Takarinda, 2012 Rural and urban Zimbabwe Retrospective cohort study 2655 2655 42
8 Tweya, 2014 (before implementa-
tion of
2011 Malawi national ART/PMTCT 
guidelines)
Urban Malawi Retrospective cohort 377 377 70
9 Tweya 2014 (after implementa-
tion of 2011 Malawi national ART/
PMTCT guidelines)
Urban Malawi Retrospective cohort 308 308 78
10 Van Rie, 2014 Urban DRC Prospective cohort study 513 513 69
11 Kumwenda, 2011 Rural and urban Malawi Retrospective cohort 996 996 38.1
12 Pepper, 2011 Urban slum, South Africa Secondary analysis of prospective 
cohort data
100 100 66
13 Ndagijimana, 2015 (Setting of 
Kicukiro)
Urban Rwanda Retrospective cohort 352 352 71
14 Ndagijimana, 2015 (Setting of 
Rulindo)
Rural Rwanda Retrospective cohort 60 60 93.8
15 Njozing, 2010 Urban and rural Cameroon Retrospective cohort 1473 1220 50.3
16 Patel, 2014 Urban DRC Prospective cohort 599 492 82.5
17 Hermans, 2012 Urban Uganda Retrospective cohort 366 228 57
18 Huerga, 2010 (short-term after 
integration)
Rural Kenya Retrospective cohort 437 325 46.2
19 Huerga, 2010 (medium term after 
integration)
Rural Kenya Retrospective cohort 477 332 41.3
20 Kanyerere, 2012 Urban Malawi Retrospective cohort 1190 1190 57.8
21 Ledibane, 2015 Rural and urban South Africa Cross-sectional 2761 2761 35.9
22 Owiti, 2015 Rural Kenya Retrospective cohort 323 323 60.7
23 Pathmanathan, 2018 Rural and urban Swaziland Retrospective cohort 466 277 98.9
24 Ansa, 2014 Urban Ghana Prospective and retrospective 
cohort
132 79 59.5
25 Van Lettow, 2011 (before policy 
to start ART as early as 2 weeks 
after commencing treatment for 
active TB
Urban Malawi Prospective cohort study 1111 1111 21.2
26 Van Lettow, 2011 (after policy 
to start ART as early as 2 weeks 
after commencing treatment for 
active TB)
Urban Malawi Prospective cohort study 1072 1072 28.5
27 Phiri, 2011 (ART started during
first 2 months of
TB treatment: 2008 reporting 
period)
Urban Malawi Case study approach 1219 1219 17
28 Phiri, 2011 (ART started during
first 2 months of
TB treatment: 2009 reporting 
period)
Urban Malawi Case study approach 1138 1138 38
22,847 21,630
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effect (p < 0.0001). There was high heterogeneity in all the 
subgroup analyses.
Figure 3 shows an assessment of the risk of publication 
bias across the estimates of ART uptake. It reveals a low 
risk of publication bias.
Barriers to and enablers of ART uptake
The barriers to and enablers of ART uptake are presented 
in Table 5.
Barriers to uptake of ART 
The themes that emerged from the studies with data on 
barriers were socioeconomic and individual level, health 
system, and clinical. The most frequent barriers under 
the socioeconomic and individual level theme were 
stigma (3 studies) [28–30];poverty/low income (2 stud-
ies) [21, 31] and younger age group (2 studies) [21, 31]. 
Concerning stigma, Levin et al.reported that all patients 
who declined from attending integrated TB/HIV services 
mentioned negative stigma surrounding HIV as their 
principal concern (perceived stigma) [29]. Wajanga et al. 
also reported perceived stigma as a barrier to HIV status 
disclosure and ART uptake in TB patients [30].Chileshe 
et al.described both perceived and enacted stigma which 
made it difficult for TB patients infected with HIV to dis-
close their HIV status and access ART [28]. The patients 
feared gossip and verbal insults (perceived stigma). They 
were isolated within households, neglected, visited less 
by relatives and friends, and experienced insults or gos-
sip (enacted stigma). Regarding poverty/low income, it 
led to lack of transport fare to travel to treatment cen-
tres especially when patients had to be accompanied as 
reported by Kumwenda et al. and Chileshe et al.[21, 28]. 
As concerns younger age, Kumwenda et  al.found that 
patients aged 15–24  years were least likely to initiate 
ART [21] while Pepper et  al.reported that age less than 
36  years was associated with not initiating ART [31]. 
Other socioeconomic and individual level barriers such 
as non-disclosure of HIV status to healthcare providers 
[22] and lack of social support network[31] are outlined 
in Table 5.
The most common subthemes under the health system 
related barriers were limited staff capacity (3 studies) [26, 
28, 32]; shortages in medical supplies (3 studies) [21, 26, 
30]; lack of infrastructure for the provision of integrated 
treatment services (2 studies) [26, 32]; poor adherence to 
or lack of treatment guidelines (2 studies) [30, 32]; and 
long enrolment process [28, 30]. Limited staff capacity 
Table 2 Studies with data on barriers to and/or enablers of ART uptake in the context of integrated HIV/TB treatment in sub-Saharan 
Africa
IDI In-depth interview, FGD focus-group discussion, DRC democratic Republic of Congo
Author, year Setting Research method/
Study design
Participants Sample size
Kumwenda, 2011 Rural and urban Malawi Mixed methods: historical cohort study 
(quantitative) and cross-sectional 
survey with IDIs (qualitative)
996 HIV/TB co-infected patients
99 newly registered TB patients for IDIs
996-quantitative
99-qualitative
Patel, 2014 Urban DRC Quantitative: Prospective cohort HIV/TB co-infected patients 492
Pepper, 2011 Urban slum,
South Africa
Quantitative: Secondary analysis of 
prospective cohort data
HIV/TB co-infected patients 100
Levin, 2006 Urban South Africa Mixed-methods cross-sectional study 
using semi-structured questionnaire 
with qualitative fields
HIV/TB co-infected persons of pre-
dominantly low socioeconomic status
85
Nansera, 2010 Rural Uganda Mixed methods: cross-sectional study 
including key informant interviews for 
qualitative data
Workers of 22 health units 88
Njozing, 2010 Rural and urban Cameroon Quantitative: retrospective cohort Staff of hospitals providing TB/HIV 
treatment and support services
1220
Ndagijimana, 2015 Rural and urban Rwanda Mixed methods:
Quantitative component: Retrospec-
tive cohort
Qualitative component: cross-sectional 
with data collection via IDIs and FGDs
-Staff of health facilities (IDIs)
-HIV/TB co-infected patients (FGDs)
24 IDIs and 12 
FGDs
Wajanga, 2014 Urban Tanzania Qualitative: Cross-sectional with data 
collection via IDIs
Hospital staff including administrators, 
laboratory technicians, pharmacists, 
and physicians
26 IDIs
Chileshe, 2010 Rural Zambia Qualitative: ethnographic case-studies HIV/TB co-infected patients and their 
households
7 case studies
Tweya, 2014 Urban Malawi Quantitative: retrospective cohort HIV/TB co-infected patients 377
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 10 of 17Kadia et al. AIDS Research and Therapy           (2021) 18:85 
presented as shortage of staff (Nansera et  al. [32], Chil-
eshe et al. [28], and Ndagijimana et al. [26]), insufficient 
skills and knowledge on integrated treatment among staff 
(Nansera et al.) [32] and turnover of staff trained on inte-
grated treatment (Ndagijimana et al.) [26]. Limited medi-
cal supply resulted from drug stock-outs or insufficiency 
as revealed by Kumwenda et al. [21], Wajanga et al. [30] 
and Nansera et al. [32]. Other health system related bar-
riers such as poor staff motivation (Ndagijimana et  al.) 
[26] and the provider failing to offer ART to TB patients 
(Kumwenda et  al.) [21]. Clinical challenges were essen-
tially drug-related and included intolerance to anti-TB 
drugs (Patel et  al.) [22], providers’ fear of drug toxicity 
(Kumwenda et al.) [21]; and contraindications to one or 
more antiretrovirals (Kumwenda et al.) [21].
Enablers of uptake of ART 
Health system and community level factors were the 
most frequently reported enablers of uptake. The most 
frequently described health system related enabling 
factors were re-enforcement of procurement, sup-
ply, and dispensation chain (5 studies) [21, 22, 26, 30, 
32]; convenience and accessibility of treatment ser-
vices (3 studies) [26, 29, 34]; and strong staff capacity 
(3 studies) [30, 32, 34]. Some strategies to strengthen 
procurement, supply and dispensation included ensur-
ing availability of sufficient medical supplies [30, 32], 
effective prescription of drugs by providers[21], and 
designating teams to provide drugs at odd times such 
as weekends [30]. Wajanga et  al. reported that easing 
policy to allow concurrent counselling and drug admin-
istration instead of separating the two procedures could 
facilitate ART initiation [30]. In the qualitative study by 
Ndagijimana et  al., providers reported that delivering 
treatment of TB and HIV at once and at the same loca-
tion enhanced quality of service and this was acknowl-
edged by patients [26]. Other strategies are mentioned 
in Table 5. As concerns strengthening of staff capacity, 
Nansera et  al. reported equipping staff with adequate 
knowledge/skills and ensuring there are enough staff 
Table 4 Quality appraisal of qualitative studies assessing barriers and/or enablers
Criteria Kumwenda, 2011 Levin, 2006 Nansera, 2010 Njozing, 2011 Ndagijimana, 2015 Wajanga, 2014 Chileshe, 2010
1. Was there a clear 
statement of the aims 
of the research?
Yes Yes Yes Yes Yes Yes Yes
2. Is a qualitative meth-
odology appropriate?
Yes Yes Yes Yes Yes Yes Yes
3. Was the research 
design appropriate to 
address the aims of the 
research?
Yes Yes Yes Yes Yes Yes Yes
4. Was the recruitment 
strategy appropriate 
to the aims of the 
research?
Yes Yes Yes Yes Yes Yes Yes
5. Was the data col-
lected in a way that 
addressed the research 
issue?
Yes Yes Yes Yes Yes Yes Yes
6. Has the relationship 
between researcher 
and participants been 
adequately considered?
No No No No No No No
7. Have ethical issues 
been taken into consid-
eration?
Yes Yes Yes Yes Yes Yes Yes
8. Was the data analysis 
sufficiently rigorous?
Yes Can’t tell Can’t tell Yes Yes Yes Yes
9. Is there a clear state-
ment of findings?
Yes Yes Yes Yes Yes Yes Yes
10. How valuable is the 
research?
Very Very Very Very Very Very Very
Overall risk of bias Minimal Moderate Moderate Moderate Moderate Moderate Moderate
Overall Rating/Com-
ment
Good Fair Fair Good Good Good Good
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for service delivery [32] while Wajanga et  al. reported 
continuing education of staff and promoting positive 
multidisciplinary approach to patient management 
[30]. Njozing et  al. also reported use of multidisci-
plinary team approach [35]. As for convenience and 
accessibility of services, studies by Njozing et  al. [35], 
Ndagijimana et  al. [26], and Levin et  al. [29] revealed 
that joint treatment services for TB and HIV was more 
convenient to patients and eased patients’ access to 
treatment which facilitates treatment uptake.
Availability of psychosocial support (2 studies) [28, 
35] was the most frequently reported enabler of ART 
uptake at the community-level. The reported types of 
psychosocial support were in the form of persons living 
with HIV support group (Chileshe et  al. [28], Njozing 
et al. [35]) and informally through support from family 
or friends (Chileshe et al.) [28]. Chileshe et al. reported 
how an HIV support group helped link a patient to 
treatment [28]. Njozing et al. reported a variety of roles 
of HIV support groups including counselling and home 
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Fig. 2 Forest plot showing individual study and pooled estimates of ART uptake. The dashed line on the Forest plot represents the overall pooled 
estimate. The grey squares and horizontal lines represent the individual study ART uptakes and their 95% confidence intervals. The size of the grey 
square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled estimate and its 95% confidence 
intervals
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visits to the sick [35]. Clinical factors enabling uptake 
were described in one study and included being a 
retreatment patient and being in HIV care at the start 
of TB treatment (Tweya et al.) [33]
Discussion
Co-delivery of TB and HIV treatment services within the 
same location is expected to enhance the control of TB 
and HIV co-pandemics by facilitating patients’ access 
to treatment commodities and ensuring efficiency in 
treatment delivery [36]. It has even been reported that 
patients offered full integration of TB and HIV treatment 
services are more likely to initiate ART than those not 
receiving integrated treatment [37]. Despite the known 
merits of integrating treatment of TB and HIV, coupled 
with compelling evidence that early ART uptake by co-
infected patients reduces mortality [38], there remain 
widespread controversies on the potential of this inter-
vention to achieve high ART uptake among co-infected 
patients in SSA.
The summary estimate for ART uptake was subopti-
mal, but this finding should be interpreted with caution 
mainly because of the high between-study variability. 
ART initiation initially depended on CD4 cell count 
even in TB/HIV co-infected patients but since 2015, 
WHO has recommended ART initiation irrespective 
of CD4 count [39]. If we had used year of ART initia-
tion policy change to categorise the studies into groups 
(before and after policy change) and then do subgroup 
analysis by year, it would not have been sensible to con-
clude that any observed subgroup effects are attribut-
able to ART initiation policy change. This is because 
we observed an extreme paucity of data from subjects 
under the new (‘test and treat’) ART initiation policy. 
Even though a good proportion of the studies were 
published after the WHO had issued new guidelines 
on ART initiation and TB/HIV collaborative activi-
ties, most studies were still based on the old policies. 
This may suggest that there have been serious delays in 
implementing the new policies which, relative to the 
old policies, are expected to reduce delays in ART ini-
tiation. And indeed, in 2019, data from WHO revealed 
that only 11% of low-and middle-income countries 
were implementing the ‘test and treat’ policy [40]. 
These notwithstanding, we observed a tendency for 
studies published after the revised TB/HIV collabo-
rative guidelines to favour much higher ART uptake 
than studies published before the revised guidelines 
and summary estimates from subgroup analysis based 
on TB/HIV collaborative activities guidelines revealed 
a much higher pooled ART uptake in the era of the 
revised guidelines. These may indicate that despite the 
suboptimal pooled ART uptake of 53% and apparent 
delays in implementing new policies, there has been an 
overall net improvement in ART uptake since 2012.
It is also worth noting that most of the studies in this 
review were retrospective and subgroup analysis showed 
that pooled ART uptake was highest for retrospective 
studies. However, these studies tended to rely on routine 
programmatic data, and the quality of such data in low-
income settings is often questionable. Prospective cohort 
studies are expected to provide more reliable data and 
subgroup analysis showed that pooled ART uptake for 
these studies was much lower than that for retrospective 
studies, but the same as the overall pooled ART uptake 
of 53%. This pooled uptake is much lower than the ART 
uptake in the general HIV-infected population in SSA in 
2019 (76% for women and 62% for men) [41]. A previous 
meta-analysis reported an ART uptake rate of 83%. How-
ever, the external validity of the review was limited by the 
thin data (just 9 studies were eligible for the review), and 
two-thirds of the studies were from South Africa [42]. In 
view of these, studies employing robust methods on a lar-
gescale to assess the effectiveness of integrated treatment 
programmes in increasing treatment outcomes among 
co-infected patients in SSA are clearly needed.
The most frequently described socioeconomic and 
patient-level barriers to ART uptake were stigma, low 
socioeconomic status, and youth. Perceived and antici-
pated stigma associated with HIV and TB may cause 
patients not to disclose their HIV status or access ART 
and in some communities, specific subgroups such 
as young males and people of low socioeconomic sta-
tus are more subject to stigma [31]. Previous reports 
have highlighted the huge contribution of HIV and TB-
related stigma to poor health seeking behaviours includ-
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Fig. 3 Funnel plot to assess publication bias across studies reporting 
ART uptake among adults enrolled for integrated treatment of TB and 
HIV in SSA.
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Table 5 Barriers and enablers of uptake of antiretroviral therapy in the context of integrated therapy for TB and HIV in SSA
Barriers to ART uptake
Health system-related
Limited staff capacity
Shortage of staff Nansera, 2010, Chileshe, 2010; Ndagijimana, 2015
Staff turnover after training Ndagijimana, 2015
Insufficient knowledge and skills on integrated treatment Nansera, 2010
Limited medical supplies e.g. drug stock-outs/insufficiency Kumwenda, 2011; Nansera, 2010; Wajanga, 2014
Lack of infrastructure for provision of integrated services Nansera, 2010; Ndagijimana, 2015
Long enrolment process Chileshe, 2010; Wajanga, 2014
Poor adherence to or lack of treatment guidelines Nansera, 2010; Wajanga, 2014
Prerequisite of a guardian during initiation Kumwenda, 2011
Insufficient staff motivation Ndagijimana, 2015
Limited HIV status disclosure patterns Chileshe, 2010
Provider failing to offer ART to patient on anti-TB Kumwenda, 2011
Delayed initiation because of high CD4 Kumwenda, 2011
Poor integration of inpatient and outpatient HIV and TB Wajanga, 2014 care which limits availability of essential services for inpatients
Clinical
Fear of drug toxicity Kumwenda, 2011
Contraindication to ≥ 1 antiretroviral drug(s) Kumwenda, 2011
Intolerance to anti-TB drugs Patel, 2014
Socioeconomic and individual level
Stigma Wajanga, 2014; Chileshe, 2010; Levin, 2006
Low socioeconomic status leading to financial constraints such as lack of money for transport to 
treatment facility
Kumwenda, 2011; Chileshe, 2010
Younger age group Kumwenda, 2011; Pepper, 2011
Male gender Pepper, 2011
Denial of HIV status Chileshe, 2010,
Failure to disclose status to provider Patel, 2014
Poor social support network Pepper, 2011
Negative coping such as use of alternative therapies e.g. witchcraft and faith healing Chileshe, 2010
Fear of HIV testing Chileshe, 2010
Pill burden Kumwenda, 2011
Sero-discordant HIV-negative partner Chileshe, 2010
Enablers of ART uptake
Health system-related
Strong staff capacity
Enough staff for service delivery Nansera, 2010
Continuing education of staff Wajanga, 2014,
Equipping staff with adequate knowledge, skills, and mentorship Nansera, 2010,
Promotion of positive multidisciplinary team approach in treatment Wajanga, 2014, Njozing, 2011
Re-enforcement of procurement, supply, and dispensation
Sufficient medical supplies Nansera, 2010; Wajanga, 2014
Ease policy to allow concurrent counseling and drug administration Wajanga, 2014
Providers strongly recommend and effectively prescribe drugs Kumwenda, 2011
Partnership with treatment partners and peer counsellors Wajanga, 2014
Designate teams for drug administration on weekends/urgent circumstances Wajanga, 2014
ART for TB/HIV co-infection delivered within ART/PMTCT service Tweya, 2014
Schedule ART at 2 months less likely to experience delay Patel, 2014
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as well as negative coping strategies such as alternative 
medicine [31, 45] as captured in this review. A previous 
systematic review also reported these factors as impor-
tant barriers to the uptake of ART in the prevention of 
maternal-to-child transmission of HIV in sub-Saharan 
Africa [46]. Psychosocial support of various types have 
been previously highlighted as primordial to reduce 
stigma, improve health seeking behaviours and disclo-
sure patterns, and empower patients socioeconomically 
[45] so as to increase uptake of ART. A previous sys-
tematic review in the general HIV population proposed 
increased in confidentiality in low-and middle-income 
settings where stigma persists [47]. Promoting strate-
gies to engage HIV-infected persons and their families 
in the treatment and care of HIV, for example, through 
community-based activities like psychosocial support 
groups and community-ART delivery groups (CARGs) 
run by HIV-infected persons [48] can be effective in 
reducing stigma, and improving uptake of and adherence 
to treatment. Household counselling is also an impor-
tant strategy to engage both patients and their families 
in reducing stigma. It is worth noting that decentralized 
treatment delivery strategies such as CARG are effective 
in reducing stigma, transport cost, hospital waiting time 
and congestion and increasing accessibility/nearness to 
treatment, which are important factors that determine 
access to HIV treatment in low-income settings [49–52]. 
A study by Chileshe et  al. included in this review dem-
onstrates how the persons living with HIV support group 
successfully linked a patient to treatment [28]. A study 
by Njozing et al. also included in this review reveals the 
huge role of these groups in counselling, home visits and 
strengthening staff capacity [35]. The importance of these 
community-driven approaches in improving uptake of 
ART in the contexts of treatment of HIV in the general 
population [53] and the prevention of mother-to-child 
transmission of HIV [46] have also been reported by pre-
vious systematic reviews of studies in sub-Saharan Africa 
[46]. Economic barriers remain a major challenge to ini-
tiate treatment and strategies to alleviate the economic 
burden of treatment have been also highlighted in a sys-
tematic review in low-and middle-income settings [47].
Shortages in HIV commodities as well as limited staff 
capacity and infrastructure tend to emerge as important 
system-level therapeutic challenges of TB/HIV treatment 
in low-income settings [54, 55] and can seriously delay 
uptake of ART and lead to attrition from ART [54]. This 
concurs with findings from a previous systematic review 
which revealed that health system issues such as staffing 
impair uptake of ART in the prevention of mother-to-
child transmission of HIV in sub-Saharan Africa [46]. In 
a recent large qualitative study in Ghana, infrastructural 
challenges and lack of staff capacity (notably, understaff-
ing) were highlighted as important challenges in provid-
ing treatment commodities in integrated treatment of 
TB and HIV [56]. These suggest that providing training 
to adequate number of designated staff, ensuring they 
have the necessary accompanying treatment resources 
(through a robust procurement and supply chain) includ-
ing therapeutic guidelines, developing short and concise 
enrolment procedures and adequate treatment infra-
structure could strengthen the health system, improve 
service quality, improve outcomes (including those 
related to drug-related challenges) and consequently 
contribute in promoting uptake of ART. Designated staff 
should receive sufficient mentorship and motivation 
through which they could be encouraged to devote extra 
time during weekends and emergency circumstances, 
collaborate in a multidisciplinary team and offer qual-
ity services for optimal treatment outcomes. The provi-
sion of mentorship to staff engaged in integrated TB/HIV 
treatment has been previously encouraged as a strategy 
Table 5 (continued)
Enablers of ART uptake
Convenience and accessibility of services Ndagijimana, 2015;
Njozing, 2011;
Levin, 2006
Efficiency and quality in service delivery Ndagijimana, 2015
Enrolment higher in public compared to faith-based hospitals Njozing, 2011
Community level
 Availability of psychosocial support
 Persons living with HIV group facilitating linkage to treatment, performing home visits, providing 
counseling, and fighting stigma
Chileshe, 2010;
Njozing, 2011
 Support and motivation from family or friends Chileshe, 2010
Clinical
 Being a retreatment patient Tweya, 2014
 Patient in HIV care at the start of TB treatment Tweya, 2014
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to improve uptake of ART in co-infected patients in 
low-income settings and could therefore be included 
in TB/HIV integrated treatment protocols in order to 
strengthen staff capacity and enhance initiation of ART 
[57]. In a previous systematic review, Ahmed and col-
leagues also emphasized on fear of side effects as a bar-
rier to ART uptake in low-and middle-income settings 
and highlighted the pivotal role of continually providing 
information on the health benefits of ART and low side 
effects of current regimens [47].
Major disruptions in TB/HIV services caused by the 
COVID-19 pandemic have further demonstrated merits 
in providing integrated and decentralized treatment ser-
vices to persons infected with TB and HIV [58]. While 
some innovations to maintain service delivery have been 
reported [58], it is worth noting that inadequate knowledge 
of pre-existing barriers to treatment compliance within 
integrated TB/HIV programmes prior to the pandemic 
may have hugely impaired the formulation of adequate 
strategies of adaptation to limit low ART uptake and attri-
tion from treatment during the pandemic. This is especially 
true of African settings where TB and HIV services already 
faced serious challenges before the pandemic occurred.
This study is not void of limitations. We excluded grey 
literature and studies published in languages other than 
English and this possibly reduced the variety of barri-
ers and enablers that were captured. Furthermore, the 
high variability between studies with estimates of uptake 
negatively affect the validity of the summary estimates of 
ART uptake, so these results should be interpreted with 
caution. Additionally, the data supporting each theme 
on barriers to and enablers of ART uptake were gener-
ally thin. Also, whilst this review provides evidence to 
improve the quality of integrated TB/HIV treatment 
services, it is limited to ART uptake in patients concur-
rently or later diagnosed with HIV and does not report 
TB-related outcomes.
Nonetheless, this study contributes to addressing the 
crucial lack of data regarding opportunities for improving 
ART uptake in the domain of integrated treatment for HIV 
and TB in SSA, the region with the highest burden of HIV/
TB co-infection worldwide. Moreover, previous reports in 
the region generally provide quantitative data on coverage 
and functionality of integrated treatment, with little atten-
tion towards qualitative data which include major drivers 
of suboptimal treatment outcomes. This study employed 
a systematic and robust approach to fill the knowledge 
gap in facilitators of uptake of ART in integrated HIV/TB 
treatment services. Consequently, the evidence generated 
is expected to be of sufficiently high quality to adequately 
inform the formulation and implementation of integrated 
HIV/TB treatment policies in SSA. Based on our find-
ings, ART uptake in programmes integrating TB/HIV 
treatment services in SSA is suboptimal and this suggests 
the important need to review strategies to improve ART 
uptake within these programmes. By exploring and syn-
thesizing evidence on a broad range of factors that deter-
mine uptake of ART in integrated HIV/TB treatment, this 
review has highlighted key intervention points to improve 
ART uptake and improve treatment outcome in pro-
grammes integrating treatment of HIV and TB in SSA.
Conclusion
The pooled ART uptake in this study was suboptimal 
even when compared to ART uptake in general HIV 
population. This suggests that programmes integrat-
ing treatment of TB and HIV in SSA do not, in gen-
eral, achieve high uptake of ART among co-infected 
patients. Nonetheless, recent studies tended to show 
much higher uptake than older studies and this may 
indicate an overall improvement in ART uptake in 
recent times. The potential to increase ART uptake 
among co-infected patients in SSA through these pro-
grammes will remain elusive unless a plethora of bar-
riers are addressed using effective interventions. The 
variety of barriers and enablers observed indicates the 
broad range of perspectives that ought to be considered 
to improve ART uptake in integrated TB/HIV treat-
ment services in SSA. Nonetheless, the recurrence of 
some specific system-level (staff capacity and medical 
supplies), and patient-level (stigma, income, and psy-
chosocial support) determinants reveals key interven-
tion points to improve ART uptake through integrated 
treatment programmes in SSA.
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